SANOFI-AVENTIS (EPA:SAN) FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of =50%

Transparency directive : regulatory news

22/02/2021 19:00


Other stories

09/03/2021 07:36
09/03/2021 01:49
09/03/2021 08:18
08/03/2021 17:58
08/03/2021 00:35
09/03/2021 09:28
09/03/2021 10:29
09/03/2021 11:26
09/03/2021 01:22
08/03/2021 18:31
09/03/2021 08:04
09/03/2021 09:36
08/03/2021 21:57
09/03/2021 07:45
09/03/2021 08:34
08/03/2021 09:30
09/03/2021 11:13
08/03/2021 12:44
08/03/2021 20:20
09/03/2021 01:50
08/03/2021 22:34
08/03/2021 21:05
09/03/2021 09:14
09/03/2021 08:33
08/03/2021 17:13
08/03/2021 09:00
09/03/2021 10:24
09/03/2021 09:53
08/03/2021 21:05
09/03/2021 10:14
09/03/2021 07:50
09/03/2021 02:35
08/03/2021 14:00
08/03/2021 08:14
08/03/2021 21:19
09/03/2021 09:09
09/03/2021 01:05
07/03/2021 23:48